1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
66A462ADEB5D0E354852577C9006D8A99
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/januvia-case-study-successful-launch-for-around-physician-patient-payer-education?opendocument
18
19opendocument
2018.206.194.83
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Sales and Marketing New Product Development and Launch Planning and Coordinating Launch Communication Activities

Januvia Case Study: Building a Successful Launch Around KOL, Physician, Patient and Payer Education

ID: 5106


Features:

Metrics, Graphics


Pages/Slides: 60


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Januvia Case Study: Building a Successful Launch Around KOL, Physician, Patient and Payer Education"

STUDY OVERVIEW

Approved in 2006 as a treatment for Type II diabetes, Januvia is a first-in-class oral dipeptidyl peptidase-4 that was greeted enthusiastically at launch by prescribers, payers and patients. One of the most notable drug launches in recent years, Januvia's market entry was impressive for not only how quickly it got to the market but also how quickly it was embraced by the marketplace. The product exceeded $750 million in sales in its first full year on the market and hit blockbuster status in 2008, its second year on the market.

Januvia's rapid market acceptance was the result of years of pre-launch work to educate the key stakeholders in the diabetes therapeutic area: KOLs, physicians, payers and patients. Given Januvia's new method of action, Merck understood the need to educate - in a cascading manner - these critical groups with targeted messages that related Januvia to each stakeholder's needs. This case study reviews the strategies and tactics Merck used to educate key stakeholders and how those efforts paid off at launch. The study is the result of primary and secondary research that includes an extensive interview with a member of Januvia's launch team and a presentation that links Januvia's education tactics/strategies to Merck's move to a new commercialization model. Some of the topics addressed in the case study are Merck's focus on primary care physicians as a key launch tactic, the importance of a focused target patient population, and use of new technologies such as video detailing and tablet PCs to educate in an effective and less costly manner. By linking qualitative information from a Januvia leader with secondary research examples involving Merck/Januvia, this research project provides a unique perspective of how pre-launch education efforts across multiple stakeholder groups can have a powerful impact on a new product launch.

KEY TOPICS

  • Speed of Launch: Keys to Success
  • Using KOLs to Position for a Successful Launch
  • Using Value to Win Over Payers
  • Physician Education: Pathway to Acceptance
  • Patient Education: Learning Self-Health Management
  • Target Patient Population: Balance Between Wide and Narrow
  • Using Technology as a Launch Tool

KEY METRICS
  • Merck Realigns & Reduces Promotional Spending
  • Share of Prescriptions and Samples for Type II Diabetes, Nov. 2006
  • Cost Per Detail, Sales Representative vs. Video
  • Length of Detail, Sales Representative vs. Video

SAMPLE LESSON LEARNED

Use Speed to Win Quick Acceptance: While Januvia had competitive pressure as motivation for launching with speed – no one knew when Novartis’ DPP-4 would be approved – the quick market acceptance of Januvia illustrates the benefit of a rapid launch sequence of educational and promotional programs.
Create a KOL Group that Cuts Across Every Different Level: To create a foundation for acceptance across the physician landscape, Merck tapped into KOLs that spanned different levels of the KOL landscape: National, Regional, Academic and Local.

METHODOLOGY
The data for this case study were collected from an executive interview with a Januvia launch leader and secondary research from Merck and other external sources.

Industries Profiled:
Pharmaceutical; Health Care


Companies Profiled:
Merck

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.